A Phase 1, First-in-human, Randomized, Double Blind, Placebo Controlled, Safety, Tolerability and Pharmacokinetic Study of ABY 039 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 24 Apr 2019
Price : $35 *
At a glance
- Drugs ABY-039 (Primary) ; ABY-039 (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions; First in man
- Sponsors Affibody
- 17 Apr 2019 Planned End Date changed from 1 Jan 2019 to 1 Mar 2020.
- 17 Apr 2019 Planned primary completion date changed from 1 Jan 2019 to 1 Mar 2020.
- 21 Mar 2018 Status changed from planning to recruiting, according to an Affibody media release.